市場調查報告書

月太(Peptide)療法-全球市場展望(2019-2027)

Peptide Therapeutics - Global Market Outlook (2019-2027)

出版商 Stratistics Market Research Consulting 商品編碼 942441
出版日期 內容資訊 英文 201 Pages
商品交期: 2-3個工作天內
價格
月太(Peptide)療法-全球市場展望(2019-2027) Peptide Therapeutics - Global Market Outlook (2019-2027)
出版日期: 2020年06月01日內容資訊: 英文 201 Pages
簡介

2019年全球月太(Peptide)治療市場將達到281.5億美元,在預測期內以11.4%的複合年增長率增長,預計到2027年將達到667.6億美元。癌症患病率的增加,強大的產品線組合的存在,以及代謝紊亂病例的增加是市場增長的驅動因素。但是,嚴格的政府審批程序法規阻礙了市場的增長。

該報告調查和分析了全球多月太(Peptide)治療市場,並提供了有關市場概況、市場趨勢、市場細分及按地區進行市場分析,瞭解競爭情況,主要公司等的系統信息。

內容

第1章執行摘要

第2章簡介

第3章市場趨勢分析

  • 促進要因
  • 抑制因子
  • 市場機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • Covid-19的影響

第4章波特的五力分析

第5章按類型劃分的全球月太(Peptide)治療市場

  • 簡介
  • 創新
  • 通用
  • 品牌

第6章全球多月太(Peptide)療法市場:製造商的類型

  • 簡介
  • 外包
  • 內部
  • 合同製造組織(CMO)

按管理途徑劃分的第七章全球月太(Peptide)治療市場

  • 簡介
  • 非經口
  • 口部
  • 粘膜
  • 注射
  • 其他管理途徑
    • 鼻子
    • 皮內

第8章合成技術在全球月太(Peptide)治療市場上的應用

  • 簡介
  • 固相月太(Peptide)合成(SPPS)
  • 液相月太(Peptide)合成(LPPS)
  • 混合技術

第9章按分子類型劃分的全球多月太(Peptide)治療市場

  • 簡介
  • 加壓素
  • 生長抑素
  • 利鈉
  • 促黃體激素(LH)-釋放激素(LHRH)
  • 胰島素
  • 免疫月太(Peptide)
  • 胰高血糖素及其類似物
  • 降鈣素

第10章按應用分類的全球月太(Peptide)治療市場

  • 簡介
  • 癌症
    • Velcade(硼替佐米)
    • Zoladex(Goserelin)
    • Lupron/Enantone/Eligard(Leuprorelin)
  • 心血管疾病
    • 整聯蛋白(依替巴月太(Peptide))
    • Angiomax(比伐盧定)
  • 代謝
    • 維埃塔(艾塞那月太(Peptide))
    • 維托扎(利拉魯月太(Peptide))
  • 呼吸系統
  • 胃腸道感染(GIT)
    • 林德斯(linaclotide)
    • Gatex(特古古浪)
  • 疼痛
  • 皮膚科
  • 抗感染症
  • 中樞神經系統
    • 可可鬆(格拉替雷)
  • 腎臟
  • 傳染病
    • Victorrelis(boceprevir)
    • Incibec(teraprevir)
  • 血液疾病
    • 卡比托爾(依蘭替尼)
    • 菲拉齊爾(烏賊)
  • 肢端肥大症
  • 其他應用
    • 過敏/免疫
    • 骨質疏鬆

第11章按最終用戶劃分的全球月太(Peptide)治療市場

  • 簡介
  • 製藥和生物技術行業
  • 醫院
  • 合同研究組織
  • 學術研究所

第12章按地區分列的全球月太(Peptide)治療市場

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東/非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東/非洲

第13章主要趨勢

  • 合同,合夥,合作,合資
  • 併購
  • 推出新產品
  • 擴展名
  • 其他主要策略

第14章公司簡介

  • Teva Pharmaceutical
  • Bachem Holding AG
  • Sanofi
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Lonza Inc.
  • GlaxoSmithKline (GSK)
  • Eli Lilly and Company
  • Bristol-Myers Squibb(BMS)
  • Merck and Co.
  • AstraZeneca PLC
  • Novo Nordisk A/S
  • Ipsen
  • Takeda Pharmaceutical Company Limited
目錄

According to Stratistics MRC, the Global Peptide Therapeutics Market is accounted for $28.15 billion in 2019 and is expected to reach $66.76 billion by 2027 growing at a CAGR of 11.4% during the forecast period. Increasing prevalence of cancer, presence of strong product pipeline portfolio and an increasing number of cases of the metabolic disorder is driving the market growth. However, stringent government regulation for the approval process is hampering the growth of the market.

Peptides represent one of a kind class of pharmaceutical compounds; it is recognized for being adequate and specific. Demand for peptides in clinical therapeutics is increasing as peptides have low production complexity as compared with that of protein-based biopharmaceuticals, which thereby reduces overall production cost.

Based on the type, the innovative segment is going to have high growth during the forecast period owing to the increasing investments by huge pharmaceuticals in R&D for the development of novel medicines and high prescription rate. By geography, Asia Pacific is going to have high growth during the forecast period owing to the vast patient pool, increasing healthcare expenditure and demand for newer advanced therapies.

Some of the key players profiled in the Peptide Therapeutics Market include Teva Pharmaceutical, Bachem Holding AG, Sanofi, Pfizer Inc., Amgen Inc., Novartis AG, Lonza Inc., GlaxoSmithKline (GSK), Eli Lilly and Company, Bristol-Myers Squibb(BMS), Merck & Co., AstraZeneca PLC, Novo Nordisk A/S, Ipsen, and Takeda Pharmaceutical Company Limited.

Types Covered:

  • Innovative
  • Generic
  • Branded

Type of Manufacturers Covered:

  • Outsourced
  • In-house
  • Contract Manufacturing Organizations (CMOs)

Route of Administrations Covered:

  • Pulmonary
  • Parenteral
  • Oral
  • Mucosal
  • Injection
  • Other Route of Administrations

Synthesis Technologies Covered:

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology

Type of Molecules Covered:

  • Vasopressin
  • Somatostatin
  • Natriuretic
  • Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • Insulins
  • Immunopeptide
  • Glucagon and Analogs
  • Calcitonin

Applications Covered:

  • Cancer
  • Cardiovascular Disorder
  • Metabolic
  • Respiratory
  • Gastro-Intestinal Infection (GIT)
  • Pain
  • Dermatology
  • Anti-infection
  • Central Nervous System
  • Renal
  • Infection
  • Hematological Disorders
  • Acromegaly
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Industries
  • Hospitals
  • Contract Research Organization
  • Academic and Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Peptide Therapeutics Market, By Type

  • 5.1 Introduction
  • 5.2 Innovative
  • 5.3 Generic
  • 5.4 Branded

6 Global Peptide Therapeutics Market, By Type of Manufacturers

  • 6.1 Introduction
  • 6.2 Outsourced
  • 6.3 In-house
  • 6.4 Contract Manufacturing Organizations (CMOs)

7 Global Peptide Therapeutics Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Pulmonary
  • 7.3 Parenteral
  • 7.4 Oral
  • 7.5 Mucosal
  • 7.6 Injection
  • 7.7 Other Route of Administrations
    • 7.7.1 Nasal
    • 7.7.2 Intradermal

8 Global Peptide Therapeutics Market, By Synthesis Technology

  • 8.1 Introduction
  • 8.2 Solid Phase Peptide Synthesis (SPPS)
  • 8.3 Liquid Phase Peptide Synthesis (LPPS)
  • 8.4 Hybrid Technology

9 Global Peptide Therapeutics Market, By Type of Molecule

  • 9.1 Introduction
  • 9.2 Vasopressin
  • 9.3 Somatostatin
  • 9.4 Natriuretic
  • 9.5 Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • 9.6 Insulins
  • 9.7 Immunopeptide
  • 9.8 Glucagon and Analogs
  • 9.9 Calcitonin

10 Global Peptide Therapeutics Market, By Application

  • 10.1 Introduction
  • 10.2 Cancer
    • 10.2.1 Velcade (Bortezomib)
    • 10.2.2 Zoladex (Goserelin)
    • 10.2.3 Lupron/ Enantone/ Eligard (Leuprorelin)
  • 10.3 Cardiovascular Disorder
    • 10.3.1 Integrilin (Eptifibatide)
    • 10.3.2 Angiomax (Bivalirudin)
  • 10.4 Metabolic
    • 10.4.1 Byetta (Exenatide)
    • 10.4.2 Victoza (Liraglutide)
  • 10.5 Respiratory
  • 10.6 Gastro-Intestinal Infection (GIT)
    • 10.6.1 Linzess (Linaclotide)
    • 10.6.2 Gattex (Teduglutide)
  • 10.7 Pain
  • 10.8 Dermatology
  • 10.9 Anti-infection
  • 10.10 Central Nervous System
    • 10.10.1 Copaxone (Glatiramer)
  • 10.11 Renal
  • 10.12 Infection
    • 10.12.1 Victrelis (Boceprevir)
    • 10.12.2 Incivek (Telaprevir)
  • 10.13 Hematological Disorders
    • 10.13.1 Kalbitor (Ecallantide)
    • 10.13.2 Firazyr (Icatibant)
  • 10.14 Acromegaly
  • 10.15 Other Applications
    • 10.15.1 Allergy/Immunological
    • 10.15.2 Osteoporosis

11 Global Peptide Therapeutics Market, By End User

  • 11.1 Introduction
  • 11.2 Pharmaceutical and Biotechnology Industries
  • 11.3 Hospitals
  • 11.4 Contract Research Organization
  • 11.5 Academic and Research Institutes

12 Global Peptide Therapeutics Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Teva Pharmaceutical
  • 14.2 Bachem Holding AG
  • 14.3 Sanofi
  • 14.4 Pfizer Inc.
  • 14.5 Amgen Inc.
  • 14.6 Novartis AG
  • 14.7 Lonza Inc.
  • 14.8 GlaxoSmithKline (GSK)
  • 14.9 Eli Lilly and Company
  • 14.10 Bristol-Myers Squibb(BMS)
  • 14.11 Merck & Co.
  • 14.12 AstraZeneca PLC
  • 14.13 Novo Nordisk A/S
  • 14.14 Ipsen
  • 14.15 Takeda Pharmaceutical Company Limited

List of Tables

  • Table 1 Global Peptide Therapeutics Market Outlook, By Region (2018-2027) ($MN)
  • Table 2 Global Peptide Therapeutics Market Outlook, By Type (2018-2027) ($MN)
  • Table 3 Global Peptide Therapeutics Market Outlook, By Innovative (2018-2027) ($MN)
  • Table 4 Global Peptide Therapeutics Market Outlook, By Generic (2018-2027) ($MN)
  • Table 5 Global Peptide Therapeutics Market Outlook, By Branded (2018-2027) ($MN)
  • Table 6 Global Peptide Therapeutics Market Outlook, By Type of Manufacturers (2018-2027) ($MN)
  • Table 7 Global Peptide Therapeutics Market Outlook, By Outsourced (2018-2027) ($MN)
  • Table 8 Global Peptide Therapeutics Market Outlook, By In-house (2018-2027) ($MN)
  • Table 9 Global Peptide Therapeutics Market Outlook, By Contract Manufacturing Organizations (CMOs) (2018-2027) ($MN)
  • Table 10 Global Peptide Therapeutics Market Outlook, By Route of Administration (2018-2027) ($MN)
  • Table 11 Global Peptide Therapeutics Market Outlook, By Pulmonary (2018-2027) ($MN)
  • Table 12 Global Peptide Therapeutics Market Outlook, By Parenteral (2018-2027) ($MN)
  • Table 13 Global Peptide Therapeutics Market Outlook, By Oral (2018-2027) ($MN)
  • Table 14 Global Peptide Therapeutics Market Outlook, By Mucosal (2018-2027) ($MN)
  • Table 15 Global Peptide Therapeutics Market Outlook, By Injection (2018-2027) ($MN)
  • Table 16 Global Peptide Therapeutics Market Outlook, By Other Route of Administrations (2018-2027) ($MN)
  • Table 17 Global Peptide Therapeutics Market Outlook, By Nasal (2018-2027) ($MN)
  • Table 18 Global Peptide Therapeutics Market Outlook, By Intradermal (2018-2027) ($MN)
  • Table 19 Global Peptide Therapeutics Market Outlook, By Synthesis Technology (2018-2027) ($MN)
  • Table 20 Global Peptide Therapeutics Market Outlook, By Solid Phase Peptide Synthesis (SPPS) (2018-2027) ($MN)
  • Table 21 Global Peptide Therapeutics Market Outlook, By Liquid Phase Peptide Synthesis (LPPS) (2018-2027) ($MN)
  • Table 22 Global Peptide Therapeutics Market Outlook, By Hybrid Technology (2018-2027) ($MN)
  • Table 23 Global Peptide Therapeutics Market Outlook, By Type of Molecule (2018-2027) ($MN)
  • Table 24 Global Peptide Therapeutics Market Outlook, By Vasopressin (2018-2027) ($MN)
  • Table 25 Global Peptide Therapeutics Market Outlook, By Somatostatin (2018-2027) ($MN)
  • Table 26 Global Peptide Therapeutics Market Outlook, By Natriuretic (2018-2027) ($MN)
  • Table 27 Global Peptide Therapeutics Market Outlook, By Luteinizing Hormone (LH)-Releasing Hormone (LHRH) (2018-2027) ($MN)
  • Table 28 Global Peptide Therapeutics Market Outlook, By Insulins (2018-2027) ($MN)
  • Table 29 Global Peptide Therapeutics Market Outlook, By Immunopeptide (2018-2027) ($MN)
  • Table 30 Global Peptide Therapeutics Market Outlook, By Glucagon and Analogs (2018-2027) ($MN)
  • Table 31 Global Peptide Therapeutics Market Outlook, By Calcitonin (2018-2027) ($MN)
  • Table 32 Global Peptide Therapeutics Market Outlook, By Application (2018-2027) ($MN)
  • Table 33 Global Peptide Therapeutics Market Outlook, By Cancer (2018-2027) ($MN)
  • Table 34 Global Peptide Therapeutics Market Outlook, By Velcade (Bortezomib) (2018-2027) ($MN)
  • Table 35 Global Peptide Therapeutics Market Outlook, By Zoladex (Goserelin) (2018-2027) ($MN)
  • Table 36 Global Peptide Therapeutics Market Outlook, By Lupron/ Enantone/ Eligard (Leuprorelin) (2018-2027) ($MN)
  • Table 37 Global Peptide Therapeutics Market Outlook, By Cardiovascular Disorder (2018-2027) ($MN)
  • Table 38 Global Peptide Therapeutics Market Outlook, By Integrilin (Eptifibatide) (2018-2027) ($MN)
  • Table 39 Global Peptide Therapeutics Market Outlook, By Angiomax (Bivalirudin) (2018-2027) ($MN)
  • Table 40 Global Peptide Therapeutics Market Outlook, By Metabolic (2018-2027) ($MN)
  • Table 41 Global Peptide Therapeutics Market Outlook, By Byetta (Exenatide) (2018-2027) ($MN)
  • Table 42 Global Peptide Therapeutics Market Outlook, By Victoza (Liraglutide) (2018-2027) ($MN)
  • Table 43 Global Peptide Therapeutics Market Outlook, By Respiratory (2018-2027) ($MN)
  • Table 44 Global Peptide Therapeutics Market Outlook, By Gastro-Intestinal Infection (GIT) (2018-2027) ($MN)
  • Table 45 Global Peptide Therapeutics Market Outlook, By Linzess (Linaclotide) (2018-2027) ($MN)
  • Table 46 Global Peptide Therapeutics Market Outlook, By Gattex (Teduglutide) (2018-2027) ($MN)
  • Table 47 Global Peptide Therapeutics Market Outlook, By Pain (2018-2027) ($MN)
  • Table 48 Global Peptide Therapeutics Market Outlook, By Dermatology (2018-2027) ($MN)
  • Table 49 Global Peptide Therapeutics Market Outlook, By Anti-infection (2018-2027) ($MN)
  • Table 50 Global Peptide Therapeutics Market Outlook, By Central Nervous System (2018-2027) ($MN)
  • Table 51 Global Peptide Therapeutics Market Outlook, By Copaxone (Glatiramer) (2018-2027) ($MN)
  • Table 52 Global Peptide Therapeutics Market Outlook, By Renal (2018-2027) ($MN)
  • Table 53 Global Peptide Therapeutics Market Outlook, By Infection (2018-2027) ($MN)
  • Table 54 Global Peptide Therapeutics Market Outlook, By Victrelis (Boceprevir) (2018-2027) ($MN)
  • Table 55 Global Peptide Therapeutics Market Outlook, By Incivek (Telaprevir) (2018-2027) ($MN)
  • Table 56 Global Peptide Therapeutics Market Outlook, By Hematological Disorders (2018-2027) ($MN)
  • Table 57 Global Peptide Therapeutics Market Outlook, By Kalbitor (Ecallantide) (2018-2027) ($MN)
  • Table 58 Global Peptide Therapeutics Market Outlook, By Firazyr (Icatibant) (2018-2027) ($MN)
  • Table 59 Global Peptide Therapeutics Market Outlook, By Acromegaly (2018-2027) ($MN)
  • Table 60 Global Peptide Therapeutics Market Outlook, By Other Applications (2018-2027) ($MN)
  • Table 61 Global Peptide Therapeutics Market Outlook, By Allergy/Immunological (2018-2027) ($MN)
  • Table 62 Global Peptide Therapeutics Market Outlook, By Osteoporosis (2018-2027) ($MN)
  • Table 63 Global Peptide Therapeutics Market Outlook, By End User (2018-2027) ($MN)
  • Table 64 Global Peptide Therapeutics Market Outlook, By Pharmaceutical and Biotechnology Industries (2018-2027) ($MN)
  • Table 65 Global Peptide Therapeutics Market Outlook, By Hospitals (2018-2027) ($MN)
  • Table 66 Global Peptide Therapeutics Market Outlook, By Contract Research Organization (2018-2027) ($MN)
  • Table 67 Global Peptide Therapeutics Market Outlook, By Academic and Research Institutes (2018-2027) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.